Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaDel Pharma has reported a net loss of $1.31m for the third quarter ended 30 September 2010, or $0.01 loss per diluted share, compared to net loss of $1.36m, or $0.02 loss per diluted share, for the comparable period in 2009.
Subscribe to our email newsletter
NovaDel Pharma’s loss from operations was $1.52m, compared to $1.28m for the comparable period in 2009.
For the nine months ended 30 September 2010, NovaDel has posted a net income of $3.73m, or $0.04 loss per diluted share, compared to a net loss of $5.2m, or $0.09 loss per diluted share, for the year ago period.
Loss from operations was $4.12m, compared to $4.79m for the year ago period.
NovaDel Pharma is a specialty pharmaceutical company developing oral spray formulations for marketed pharmaceutical products.